Abstracts tagged "Vasculitis"

Abstract Number: 0489 • ACR Convergence 2022
Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers
Laurent Sailler¹, Kim Ly², Hubert De Boysson³, Brigitte Granel⁴, Maxima Samson⁵, Christian Agard⁶, Laurence Bouillet⁷, Magnan Julie⁸, Marc Lambert⁹, Arsene Mekinian¹⁰, Lea Tarallo¹, Eric Liozon², Gregory Pugnet¹¹, Jean Luc Davignon¹, Achille Aouba¹², Aurélie Daumas⁴, Quentin Gomes de Pinho⁴, bernard bonnotte¹³, simon parreau², Samuel Deshayes¹² and GEFA Collaborative group¹⁴, ¹CHU Toulouse, Toulouse, France, ²CHU Limoges, Limoges, France, ³Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ⁴AP-HM, Marseille, France, ⁵Dijon University Hospital, Dijon, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷Grenoble University Hospital, Grenoble, France, ⁸CHU Tours, Tours, France, ⁹CHU Lille, Lille, France, ¹⁰AP-HP, Hopital Saint Antoine, Paris, France, ¹¹CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, ¹²CHU Caen, Caen, France, ¹³Centre Hospitalo-Universitaire de Dijon, Dijon, France, ¹⁴Saint Joseph Hospital, Marseille, France
Background/Purpose: In 2016, French Internal medicine physicians collaborating in the Groupe d'Etude Français de l'Arterite à cellules géantes (GEFA) created a common database to build…
Abstract Number: 1080 • ACR Convergence 2022
Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials
Florence Delestre¹, Pierre Charles², Loïc Guillevin³, Raphaël Porcher⁴ and Benjamin Terrier³, ¹cochin Hospital, Paris, France, ²Institut Mutualiste Montsouris, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…
Abstract Number: 1555 • ACR Convergence 2022
Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study
Luigi Boiardi¹, PIERLUIGI MACCHIONI², Francesco Muratore¹, GIULIA KLINOWSKI³, ELENA GALLI¹, FEDERICA MACALUSO³, MASSIMILIANO CASALI¹, GIULIA BESUTTI¹ and Carlo Salvarani⁴, ¹Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ³IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Few studies compared the demographic, clinical, laboratory and imaging features, and outcomes of Takayasu arteritis (TAK) and large-vessel giant cell arteritis (LV-GCA). Aim of…
Abstract Number: 1577 • ACR Convergence 2022
Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life
Sarah Mann¹, Aamir Hussain², Anisha Dua³, Angelina Patrone⁴, Kalen Larson⁵, Peter Merkel⁶ and Robert Micheletti⁷, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Georgetown University, Washington, DC, ³Northwestern University, Chicago, IL, ⁴Patient Partner, Philadelphia, PA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous manifestations of vasculitis can cause pruritus, pain, and ulceration, and their psychosocial impacts may be significant. However, the quality-of-life (QoL) impact of skin…
Abstract Number: 0143 • ACR Convergence 2022
National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol
José Luis Martín-Varillas¹, Lara Sánchez-Bilbao², Vanesa Calvo Río³, Alf Adán⁴, Inés Hernanz Rodríguez⁴, Emma Beltrán Catalán⁵, Sonia Castro Oreiro⁶, Patricia Fanlo⁷, Alvaro Garcia⁸, Ignacio Torre⁹, Miguel Cordero Coma¹⁰, Juan Ramón de Dios¹¹, A. Garcia-Aparicio¹², Marisa Hernandez Garfella¹³, Amalia Sánchez Andrade¹⁴, A. García-valle¹⁵, Olga Maiz¹⁶, Juan Roberto Miguelez Sanchez¹², Sergio Rodriguez Montero¹⁷, Ana Urruticoechea¹⁸, Raul Veroz¹⁹, Arantxa Conesa²⁰, Cristina Fernández-Carballido²¹, Vega Jovani Casano²², Olga Martinez²³, Patricia Moya Alvarado²⁴, Susana Romero Yuste²⁵, Paula Rubio Muñoz²⁶, eva Peña Sainz-Pardo²⁷, Marta Garijo Bufort²⁸, José Luis Hernández² and Ricardo Blanco²⁹, ¹Hospital de Laredo, Laredo, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴H. Clinic, Barcelona, Spain, ⁵Hospital del Mar, Barcelona, Spain, ⁶H. Universitario Joan XXIII, Barcelona, Spain, ⁷Complejo Hospitalario de Navarra, Navarra, Spain, ⁸Hospital Tajo, Madrid, Spain, ⁹Hospital de Basurto, Basurto, Spain, ¹⁰Hospital de León, León, Spain, ¹¹Hospital de Araba, Araba, Spain, ¹²Hospital Universitario de Toledo, Toledo, Spain, ¹³Hospital Universitario General de Valencia, València, Spain, ¹⁴Hospital Universitario Lucus Augusti, Lugo, Spain, ¹⁵Completo Asistencial Palencia, Palencia, Spain, ¹⁶Hospital Universitario de Donostia, San Sebastián, Spain, ¹⁷Virgen de Valme University Hospital, Sevilla, Spain, ¹⁸Hospital Can Misses, Ibiza, Spain, ¹⁹Hospital de Mérida, Mérida, Spain, ²⁰Hospital Universitario de Castellón, València, Spain, ²¹Agencia Valenciana de Salud, Alicante, Spain, ²²National Health system, Alicante, Spain, ²³Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²⁴Hospital Parc Tauli, Barcelona, Spain, ²⁵Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁶H. Esperit Sant, Barcelona, Spain, ²⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁸Hospital Sagunto, València, Spain, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Adalimumab remains the only biologic approved by the EMA and FDA for the treatment of noninfectious uveitis. There are few reports on the effectiveness…
Abstract Number: 0466 • ACR Convergence 2022
Assessment of Probability Scores to Predict Giant Cell Arteritis
Chadi Sargi¹, Stephanie Ducharme-Benard², Valerie Benard³, Rosalie-Selene Meunier⁴, Carolyn Ross⁵ and Jean-Paul Makhzoum⁶, ¹University of Montreal, Laval, Canada, ²Hopital Sacre-Coeur, Montréal, QC, Canada, ³University of Montreal, Saint-Ambroise-de-Kildare, Canada, ⁴Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, ⁵University of Montreal, Montréal, QC, Canada, ⁶Hopital du Sacre-Coeur de Montreal, Montréal, QC, Canada
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis but remains challenging to diagnose. In the past years, many probability tools have been…
Abstract Number: 0493 • ACR Convergence 2022
MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center
Matthias Froehlich¹, Thorsten A. Bley², Marc Schmalzing³, Michael Gernert¹, Rudolf A. Werner⁴, Jost Hillenkamp⁵, Karl Georg Haeusler⁶ and Konstanze V. Guggenberger², ¹University Hospital Wuerzburg, Dpt. of Internal Medicine II, Wuerzburg, Germany, ²University Hospital Wuerzburg, Dpt. of Radiology, Wuerzburg, Germany, ³University Hospital Wuerzburg, Wuerzburg, Germany, ⁴University Hospital Wuerzburg, Dpt. of Nuclear medicine, Wuerzburg, Germany, ⁵University Hospital Wuerzburg, Dpt. of Ophtalmology, Wuerzburg, Germany, ⁶University Hospital Wuerzburg, Dpt. of Neurology, Wuerzburg, Germany
Background/Purpose: Imaging techniques for the detection of mural inflammation are cornerstones in the diagnosis of giant cell arteritis (GCA). Magnetic resonance imaging (MRI) and ultrasound…
Abstract Number: 1081 • ACR Convergence 2022
Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
Elizabeth Nettleton¹, Sebastian Sattui², Zachary Wallace³ and Mike Putman¹, ¹The Medical College of Wisconsin, Milwaukee, WI, ²University of Pittsburgh, Pittsburgh, PA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that may affect patients with ANCA vasculitis (AAV). Current guidelines conditionally recommend PJP prophylaxis for patients…
Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Alba Herrero-Morant¹, José Luis Martín-Varillas², Santos Castañeda³, Olga Maiz⁴, Julio Sánchez-Martín⁵, Norberto Ortego⁶, Enrique Raya⁷, Águeda Prior-Español⁸, Clara Moriano⁹, Rafael Melero¹⁰, Genaro Graña-Gil¹¹, Ana Urruticoechea¹², Angel Ramos¹³, Marta Loredo-Martínez¹⁴, Eva Salgado-Pérez¹⁵, Francisca Sivera¹⁶, Ignacio Torre¹⁷, F. Javier Narváez¹⁸, Jose Luis Andreu¹⁹, Olga Martinez²⁰, Ricardo Gómez-de la Torre²¹, Sabela Fernandez-Aguado²², Susana Romero Yuste²³, iñigo Gonzalez-Mazon⁵, Carmen Alvarez Reguera⁵, David Martínez-López⁵, José Luis Hernández⁵, Miguel Ángel González-Gay²⁴ and Ricardo Blanco²⁵, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital de Laredo, Laredo, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Hospital Universitario de Donostia, San Sebastián, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Medicine Department, Universidad de Granada, Granada, Spain, ⁷Hospital San Cecilio, Granada, Spain, ⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁹Complejo Asistencial Universitario de León, León, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Hospital Universitario de A Coruña, A Coruña, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Complejo Hospitalario de Soria, Soria, Spain, ¹⁴Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ¹⁶Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁷Hospital de Basurto, Basurto, Spain, ¹⁸Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²²Hospital Universitario de Cabueñes, Gijon, Spain, ²³Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
Abstract Number: 1578 • ACR Convergence 2022
Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Francis Lao¹, Cal Robinson², Megan Schlorff¹, Joycelynn Ewusie³, KAREN BEATTIE¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²The Hospital for Sick Children, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
Abstract Number: 0146 • ACR Convergence 2022
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
Lara Sánchez-Bilbao¹, Javier Loricera², Santos Castañeda³, Clara Moriano⁴, F. Javier Narváez⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa⁹, Paloma Vela-Casampere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesús Carlos Fernández-López¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, Julio Sánchez-Martín¹, Mónica Calderón-Goercke¹, José Luis Hernández¹, Miguel Ángel González-Gay¹⁹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA). Clinical trials with TCZ in GCA were performed with intravenous (iv)…
Abstract Number: 0467 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
Jacob Sode¹, Jens Rathmann¹, Anna Wilding², Carl Turesson³ and Aladdin Mohammad¹, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…
Abstract Number: 0494 • ACR Convergence 2022
Risk for Visual Loss in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹, Lene Kristin Brekke², Tanaz Kermani³, Oyvind Molberg⁴ and Andreas Diamantopoulos⁵, ¹Martina Hansens Hospital, Hosle, Norway, ²Haugesund Revmatismesykehus, Haugesund, Nepal, ³University of California Los Angeles, West Hills, CA, ⁴Oslo University Hospital, Oslo, Nepal, ⁵Akershus University Hospital, Lørenskog, Norway
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Permanent visual loss is a feared complication reported in up to 19% of…
Abstract Number: 1082 • ACR Convergence 2022
Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
Pratyusha Banik¹, Marcia Friedman², Daniela Ghetie³, Dongseok Choi⁴ and Margaret Brophy¹, ¹Oregon Health & Science University, Portland, OR, ²Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, ³Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Lake Oswego, OR, ⁴OHSU-PSU School of Public Health, Portland, OR
Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data…
Abstract Number: 1557 • ACR Convergence 2022
Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center
Belén Atienza-Mateo¹, Alfonso del Peral-Fanjul², Veronica Pulito-Cueto³, Diana Prieto-Peña¹, Miguel Ángel González-Gay⁴ and Ricardo Blanco⁵, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, Spain, ³IDIVAL, Santander, Spain, ⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and mucocutaneous manifestations of Behçet's disease (BD) are globally recognized and widely studied [Arthritis Rheumatol. 2019 Dec;71(12):2081-2089, Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].